目的:为了评估可行性,安全,高强度聚焦超声(HIFU)和微波消融(MWA)治疗肝脏小转移性肿瘤的疗效。
方法:回顾性评估2016年1月至2021年12月在遂宁市中心医院接受HIFU(n=28)或MWA(n=30)治疗的58例小肝转移瘤患者。比较两组的人口统计学和临床特征。
结果:与MWA组相比,HIFU组的手术时间更长,住院费用更低。术后住院次数,肿瘤消融率,手术后1个月,两组的临床反应和控制率没有显着差异。术后并发症的发生率,如发热,肝功能障碍,损伤,疼痛,胆漏在两组之间没有差异。1年和3年累积生存率分别为96.4%和52.4%,分别,在HIFU和93.3%和51.4%之后,分别,在MWA之后,这并不代表显著差异。
结论:HIFU是一种安全可行的治疗肝脏小转移瘤的方法。与MWA相比,HIFU与较低的住院费用有关,减少创伤,术后并发症少,使其成为肝转移性肿瘤的有希望的新的局部消融治疗选择。
OBJECTIVE: To evaluate the feasibility, safety, and efficacy of high-intensity focused ultrasound (HIFU) and microwave ablation (MWA) for the treatment of small liver metastatic tumors.
METHODS: Fifty-eight patients with small liver metastatic tumors who underwent HIFU (n = 28) or MWA (n = 30) at Suining Central Hospital between January 2016 and December 2021 were retrospectively evaluated. Demographic and clinical characteristics were compared between the two groups.
RESULTS: Operation times were longer and hospitalization costs were lower in the HIFU group than in the MWA group. Postoperative hospitalization times, tumor ablation rates, and clinical response and control rates did not differ significantly between the two groups 1 month after surgery. Rates of postoperative complications such as fever, liver dysfunction, injury, pain, and biliary leakage did not differ between the two groups. The 1- and 3-year cumulative survival rates were 96.4% and 52.4%, respectively, after HIFU and 93.3% and 51.4%, respectively, after MWA, which did not represent significant differences.
CONCLUSIONS: HIFU is a safe and feasible method of treating small liver metastatic tumors. Compared with MWA, HIFU was associated with lower hospitalization costs, reduced trauma, and fewer postoperative complications, making it a promising new local ablative treatment option for liver metastatic tumors.